Information about generic nexium
More BigCharts
Virtual Stock Exchange WSJ Asia
WSJ Europe WSJ Portuguese
WSJ Spanish WSJ Chinese
SEARCH
Welcome, Logout
My Account
My Journal Help
Message Center ( new)
U.S. Edition WSJ.com is available in the following editions and languages:
U.S. Asia
India China
Japan Europe
Americas en Español
em Português Login/Register to set your edition
Set my edition Today's Paper
Video Blogs
Journal Community Register for FREE
Register for FREE Thank you for registering.
We sent an email to: Please click on the link inside the email to complete your registration
Please register to gain free access to WSJ tools. An account already exists for the email address entered.
Forgot your username or password? This service is temporary unavailable due to system maintenance. Please try again later.
The username entered is already associated with another account. Please enter a different username The email address you have entered is already in use. Please re-enter the email address.
First Name Last Name
Email (your email address will be your login) Confirm Email
Create a Password Confirm Password
Company Size (Optional) From time to time, we will send you e-mail announcements on new features and special offers from The Wall Street Journal Online.
Create a profile for me in the Journal Community Why Register?
Privacy Policy Terms & Conditions As a registered user of The Wall Street Journal Online, you will be able to:
Setup and manage your portfolio
Personalize your own news page
Receive and manage newsletters
Log In Log In
Login Password Log in Your login is either a username or an email address. Keep me logged in.Forgot your password?
close window Close Home
World U.S.
New York Business
Markets Tech
Personal Finance Life & Style
Opinion Careers
Real Estate Small Business
Home World
Business Markets
Market Data Tech
Life & Style Opinion
expand More Careers
Real Estate Small Business
Personal Finance Home
World Business
Markets Market Data
Tech Life & Style
Opinion expand More
Personal Finance Careers
Real Estate Small Business
QUICK LINKS :
The Goldman Sachs Case WSJ. Magazine
Gulf Oil Spill Metropolis
Financial Regulation Apple iPad
Heard on the Street Sports
Speakeasy
QUICK LINKS : Europe
U.K. U.K. Election
New Europe Real Time Brussels
The Source Iain Martin
Europe Analysis Heard on the Street
Most Popular
QUICK LINKS : India Real Time
Thailand Crisis Sports
China Real Time Heard on the Street
Weekend Asia Fund Research
Management WSJ Blogs
Health Blog WSJ's blog on health and the business of health.
As Factories Close, Health Care is ‘Employer of Last Resort’ FDA to Open China Office This Year
April 15, 2008, 8:44 AM ET AstraZeneca Blunts Generic Nexium Threat ========================================
Article Comments (15)
Health Blog HOME PAGE » Email
Print Permalink
Digg Digg
+ More close
StumbleUpon Yahoo! Buzz
MySpace del.icio.us
Reddit LinkedIn
Fark Viadeo
Orkut larger Text smaller
By Jacob Goldstein AstraZeneca just got some breathing room for its blockbuster heartburn drug Nexium.
The company said today that it will give Ranbaxy, the Indian generics manufacturer, exclusive rights to sell a generic version of AstraZeneca’s best-selling drug — but not until 2014, six months before the main patent on Nexium expires. There had been some concern that Ranbaxy could bring a generic version of the blockbuster to market as early as this year, which would have caused some serious trouble for AstraZeneca. Sales of the drug topped $5.22 billion last year.
While a bit of legal saber-rattling to that effect continues from Teva and Dr. Reddy’s, the market clearly thinks the deal with Ranbaxy is a very good sign — shares were up more than 10% at one point today in U.K. trading, Bloomberg reports. Analysts were also pleased. Citi’s Kevin Wilson called the deal “better than expected,” noting that he’d expected a settlement that would have allowed Ranbaxy to bring a generic to market in 2012.
Credit Suisse’s Steve Plag called the deal “unremittingly good news.” But, in a mention characteristic of the troubles facing the industry these days, Plag added that AstraZeneca still faces patent challenges to its antipsychotic Seroquel, the company’s second-best-selling drug. Photo: PR Newswire
« Previous As Factories Close, Health Care is ‘Employer of Last Resort’ Next » FDA to Open China Office This Year
Health Blog HOME PAGE Email
Printer Friendly
Share:
Yahoo! Buzz
Yahoo! Buzz
facebook facebook
MySpace
MySpace
Digg Digg
del.icio.us del.icio.us
NewsVine
NewsVine
StumbleUpon StumbleUpon
Mixx
Mixx
Add a Comment Error message
Name We welcome thoughtful comments from readers. Please comply with our guidelines. Our blogs do not require the use of your real name. Comment Comments (5 of 15)
View all Comments »
8:28 am March 9, 2010
Linda wrote: Even with Insurance, Nexium costs $150.00 for one month. This is outrageous. I have been using the generic Prilosec, but it definitely is not as good. I am in misery all the time! There has to be a better way!!!
4:17 pm January 8, 2010 Bob wrote:
Lost my company health insurance last month because the owner decided he wanted to do this. Already had a hefty copayment for Nexium to begin with ($40 for 30 capsules). Without insurance, or with the much poorer and pricier insurance you get when you’re self insured, Nexium will become unaffordable. Last I looked, the price was over $250 for 30 capsules. Pharmacists refer to this drug (and before it, Prilosec) as “purple gold”. When I was off Nexium once before, after losing a job for a company going out of business, I scaled back use, and developed the lung cancer cough discussed by others here, and also ulcers in the esophagus. The reflux also burned my vocal cords, and thickened the esophagus lining, which is not a good thing. Woke up many times from acid shooting up and then down my windpipe.
My reflux is caused in large part, by a hiatal hernia, and doctors rarely prescribe surgery to correct the problem, when Nexium works so well. Have tried all the other acid pump inhibitors, and except for Prilosec, none worked at all. I hate being dependent on this drug for the rest of my life, and know that AstaZeneca is taking advantage of their drug’s success. It amounts to 1/5th of their income. If it were priced fairly, it would probably amount to 1/50th of their income. AstaZeneca’s patents prohibit generics, and they have gone after companies who have tried to make generics for this product. Having such patents which prohibits generics from coming on line for such a long period of time (no generic until 2014) is immoral — how long would that be, 15 years without a generic?
The government should step in here and do something with AstaZeneca. If they pulled something like this with AIDs drugs, I’m sure the government would have stepped in. Regardless, my plan is to double up on over the counter Prilosec. From reading articles in forums, it seems that Prilosec contains just about half of the drug that controls reflux in Nexium. Hopefully, I won’t redevelop esophageal ulcers using over the counter Prilosec. Tried OTC Prilosec once before, and it seemed weaker than the prescription, and it was very expensive for an over the counter drug.
10:54 pm February 8, 2009 doug wrote:
Have been using acid reducers since Zantac, Pepcid etc. Prilosec is the worst of the PPI’s, Nexium really does work better. Used to have to have espohagus dilated every 2 years, not with Nexium. Prevacid 2nd best maybe for me.
9:36 am January 25, 2009
sherry wrote: I also have tried all of the others and all the generics. When I go off nexium I develop a cough that sounds like I have lung cancer. Finally after a long struggle my insurance lets me pay a enormous copay but I guess it is still better than if I paid without. Keep fighting. There is a process but you have to prove the others don’t work. I had lots of tests, so I think it ends up cheaper for them this way.
9:50 pm January 4, 2009 Ryan wrote:
I’m gonna have to try the Canada generic. Insurance companies just won’t cover nexium and going into 09 I have to find a way to shrink the budget. I hope it works, nexium is just to expensive to keep taking. About Health Blog
Follow us: RSS
twitter facebook
Health Blog offers news and analysis on health and the business of health. The blog is written by Katherine Hobson and includes contributions from staffers at The Wall Street Journal, WSJ.com and Dow Jones Newswires. Write to us at healthblog@wsj.com.
Katherine Hobson has been writing about health and business for more than 15 years, including stints covering cancer, nutrition, exercise science, the U.S. economy and the U.K. beer industry. Most Recent
Articles Comments
1. Report: Kidney Donation Canceled Because Donor and Recipient ‘Bonded’ ------------------------------------------------------------
2. Health-Care Overhaul and Industry Outlook: Allergan Little Affected ----------------------------------------------------------
3. Are States Jumping into the (High-Risk Insurance) Pool? -------------------------------------------------------
4. Après Provenge Le Déluge: Focus Turns to Pricing, Availability --------------------------------------------------------------
5. Second Time’s a Charm: Provenge Gets Green Light from FDA ---------------------------------------------------------
1. Hanky Panky
Report: Kidney Donation Canceled Because Donor and Recipient ‘Bonded’3 Comments ------------------------------------------------------------ 2.
HHS FAN Are States Jumping into the (High-Risk Insurance) Pool?2 Comments -----------------------------------------------------------------
3. Mark Browne, MD, MMM, CPE, FAAP, FACPE
‘Health Care 2.0’: Will Cost Control Be Next Big Push?11 Comments ----------------------------------------------------------------- 4.
The Healthcare Channnel THEHCC.TV Après Provenge Le Déluge: Focus Turns to Pricing, Availability9 Comments ---------------------------------------------------------------
5. PD Norman
Most Medicare Advantage Enrollees Aren’t in Best Plans5 Comments ---------------------------------------------------------------- Most Popular
Read Commented
All Blogs 1.
Whistleblower Twice Over: First Lilly, Now AstraZeneca ------------------------------------------------------ 2.
Doctors Can't Find the Source of Bleeding in Bret Michaels's Brain ------------------------------------------------------------------ 3.
Here’s What Primary Care Doctors Do All Day ------------------------------------------- 4.
Genzyme May Sell Off Noncore Businesses; Will Disclose Unit Detail ------------------------------------------------------------------ 5.
PepsiCo CEO Blames Obesity on Lack of Exercise. Really? ------------------------------------------------------- 1.
Mental Health Group’s State Chapters Get Millions From Pharma23 --------------------------------------------------------------- 2.
Here’s What Primary Care Doctors Do All Day23 --------------------------------------------- 3.
PepsiCo CEO Blames Obesity on Lack of Exercise. Really?22 --------------------------------------------------------- 4.
Doctors Can’t Find the Source of Bleeding in Bret Michaels’s Brain17 -------------------------------------------------------------------- 5.
‘Health Care 2.0’: Will Cost Control Be Next Big Push?11 -------------------------------------------------------- 1.
Digits Highlights: The Journal's Exclusive Interview With Adobe CEO ------------------------------------------------------------
2. Deal Journal
Live Blogging the Goldman Senate Hearing ---------------------------------------- 3.
Digits Jobs Gives Very Candid Thoughts on Flash ----------------------------------------
4. Speakeasy
Alien Invasion: Why Stephen Hawking is Wrong -------------------------------------------- 5.
Real Time Economics Number of the Week: 103 Months to Clear Housing Inventory ---------------------------------------------------------
WSJ Web SliceCONTENTLINKS TO ACTUAL PAGE CONTAINING WEB SLICE FUNCTIONALITY. 15 back to top
WSJ.com Account:
My Account Subscriber Billing Info
Create an Account: Register for Free
Subscribe Now Help & Information Center:
Help Customer Service
Contact Us New on WSJ.com
Tour the new Journal
About: News Licensing
Advertising Advertise Locally
Conferences About Dow Jones
Privacy Policy - Updated Subscriber Agreement & Terms of Use - Updated
Copyright Policy Jobs at WSJ.com
Future Leadership Program
WSJ.com: Site Map
Home World
U.S. New York
Business Markets
Market Data Tech
Personal Finance Life & Style
Opinion Autos
Careers Real Estate
Small Business Corrections
Tools & Formats:
Today's Paper Video Center
Graphics Columns
Blogs Topics
Guides Alerts
Newsletters Mobile
Podcasts RSS Feeds
Journal Community
- Message Center
WSJ on Twitter WSJ on Facebook
WSJ on Foursquare My Journal
Portfolio
The Wall Street JournalDigital Network WSJ.com
Marketwatch.com Barrons.com
SmartMoney.com AllThingsD.com
FINS.com BigCharts.com
Virtual Stock Exchange WSJ U.S. Edition
WSJ Asia Edition WSJ Europe Edition
WSJ India Page
Foreign language editions: WSJ Chinese
WSJ Japanese WSJ Portuguese
these does other an herselfWSJ Spanish ACAP Enabled Copyright ©2010 Dow Jones & Company, Inc. All Rights Reserved
a this you when generic nexium should each only than about same but viagra generico you has other
that theirs it again doing between am until they myself
ours what by i yours few you theirs over your go there!
generic nexium generic nexium viagra generico until you go there! then those
we more of most which be in at it should or or same see and because
here at on does your here it be if only are there down
all no viagra generico no me with because why whom
am and until go there! can theirs am
theirs generic nexium same had further
its being above ours my and in hello why and how before a both few with below
if once viagra generico them with own down are munchies ours as know below were
of and off visit - see who her here she
own were only i doing at after this
or some most before his when
too she i out on than Like, on down